{'fraction_non_alphanumeric': 0.04066073697585769, 'fraction_numerical': 0.018424396442185513, 'mean_word_length': 5.5625, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Subcutaneous glucose monitoring with GlucoDay®: comparison of the results to those obtained with the Endocrine Artificial Pancreas

OBJECTIVE: This study was undertaken to assess the accuracy of GlucoDay® — a portable detector of subcutaneous glucose — by comparing the results to those obtained by Biostator® an established and reliable method for continuous glucose measurement in whole blood. DESIGN: Subjects with type 1 diabetes (n:6), subjects with type 2 diabetes (n:6), and six healthy controls were studied for 24 hours; they consumed three main meals. The GlucoDay® was connected to the subjects by inserting a microfibre probe into the periumbilical subcutaneous area, whilst the Biostator® was inserted by a double-lumen catheter into an antecubital vein. A third catheter was inserted into a separate vein for blood withdrawal to measure glucose by the hexokinase method. RESULTS: The three methods (GlucoDay®-Biostator®-hexokinase) were equally accurate in measuring glucose levels (p=0.233, Kruskall-Wallis test). The glucose measurements performed with GlucoDay® and Biostator® were significantly correlated with those performed with hexokinase (p<0.001, r2=66.65% and p<0.001, r2=64.4%, respectively, using simple regression analysis). CONCLUSIONS: Measurements of glucose fluctuations in the subcutaneous tissue with the GlucoDay® were close to those in blood determined by the Biostator®. GlucoDay® is therefore a reliable method for continuous glucose monitoring and may prove useful for optimizating treatment in patients with type 1 or type 2 diabetes.